Holen Sie sich die Stockscreener-App
2.90
4.29%
-0.13
Handel nachbörslich:
2.93
0.03
+1.03%
Schlusskurs vom Vortag:
$3.03
Offen:
$2.92
24-Stunden-Volumen:
20,340
Relative Volume:
0.19
Marktkapitalisierung:
$1.03B
Einnahmen:
$890.87M
Nettoeinkommen (Verlust:
$-115.85M
KGV:
-8.893
EPS:
-0.3261
Netto-Cashflow:
$-104.29M
1W Leistung:
+4.32%
1M Leistung:
-7.94%
6M Leistung:
-11.04%
1J Leistung:
-38.69%
1-Tages-Spanne:
$2.89
$2.925
1-Wochen-Bereich:
$2.75
$3.03
52-Wochen-Spanne:
$2.308
$4.48
Evotec Se Adr Stock (EVO) Company Profile
Compare EVO vs TAK, HLN, TEVA, ZTS, UTHR
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
EVO
Evotec Se Adr
|
2.91 | 1.08B | 890.87M | -115.85M | -104.29M | -0.3261 |
TAK
Takeda Pharmaceutical Co Adr
|
15.87 | 51.34B | 29.91B | 1.30B | 3.49B | 0.4056 |
HLN
Haleon Plc Adr
|
9.24 | 41.15B | 14.54B | 2.22B | 2.58B | 0.4871 |
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
34.63 | 39.67B | 17.53B | 1.58B | 444.18M | 1.3457 |
ZTS
Zoetis Inc
|
80.24 | 34.09B | 9.51B | 2.64B | 2.14B | 6.0361 |
UTHR
United Therapeutics Corp
|
578.43 | 24.13B | 3.17B | 1.29B | 1.01B | 27.09 |
Evotec Se Adr Stock (EVO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-15 | Fortgesetzt | H.C. Wainwright | Buy |
| 2026-02-03 | Eingeleitet | Berenberg | Buy |
| 2025-04-24 | Hochstufung | Deutsche Bank | Sell → Hold |
| 2024-10-07 | Herabstufung | Jefferies | Buy → Hold |
| 2024-08-08 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2024-07-29 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2024-07-11 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2024-04-12 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-01-18 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
| 2023-06-23 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2023-06-16 | Herabstufung | BofA Securities | Buy → Neutral |
| 2023-06-08 | Hochstufung | Citigroup | Neutral → Buy |
| 2023-04-04 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2022-12-09 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-11-16 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-08-10 | Herabstufung | Morgan Stanley | Overweight → Underweight |
| 2022-03-02 | Fortgesetzt | Cowen | Outperform |
| 2022-01-07 | Fortgesetzt | Citigroup | Neutral |
Alle ansehen
Evotec Se Adr Aktie (EVO) Neueste Nachrichten
Evotec SE stock (DE0005664809): Steady FY 2025 results amid US expansion - AD HOC NEWS
Evotec AG Earnings Call Balances Pain With Promise - The Globe and Mail
Evotec SE stock (DE0005664809): Drug discovery leader eyes US biotech growth - AD HOC NEWS
Evotec places €116.1 million convertible bonds due 2033 - Investing.com UK
Evotec places €116.1 million convertible bonds due 2033 By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Recent price gains signal short-term momentum - AD HOC NEWS
Evotec SE stock (DE0005664809): HC Wainwright cuts Q2 earnings outlook - AD HOC NEWS
Boyd Gaming posts downbeat Q1 results, joins Coursera, Evotec and other big stocks moving lower in Friday's pre-market session - MSN
Evotec SE stock (DE0005664809): Q1 2026 results show sharp revenue drop amid restructuring - AD HOC NEWS
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges - Investing.com Canada
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates By Investing.com - Investing.com Nigeria
Evotec Q1 2026 slides: revenue drops 22% as transformation accelerates - Investing.com
Earnings call transcript: Evotec Q1 2026 sees revenue drop amid market challenges By Investing.com - Investing.com South Africa
Evotec reports wider quarterly loss, misses revenue expectations By Investing.com - Investing.com Canada
Evotec reports wider quarterly loss, misses revenue expectations - Investing.com
Evotec's Share Price Surges! Summer Rally for Desert Gold? Rheinmetall Shares Heading Toward EUR 2,000? - news.financial
Evotec SE Stock (DE0005664809): Q1 2026 Results Due Today - AD HOC NEWS
Evotec nominates Wolfgang Hofmann to supervisory board By Investing.com - Investing.com Australia
Evotec nominates Wolfgang Hofmann to supervisory board - Investing.com
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Sahm
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin By Investing.com - Investing.com Australia
Boyd Gaming Posts Downbeat Q1 Results, Joins Coursera, Evotec And Other Big Stocks Moving Lower In Friday - Benzinga
Evotec names Claire Hinshelwood as CFO, replacing Paul Hitchin - Investing.com
Middle East Conflict Weighs on Markets: Food Supply Chains Become a Key Issue – MustGrow, K+S, Evotec, and BioNTech in the Spotlight - news.financial
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough for biotech recovery? - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery pipeline strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery platform strong enough to unlock biotech upsid - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for steady ups - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery partnership model strong enough for biotech re - AD HOC NEWS
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock biotech upside? - AD HOC NEWS
Evotec appoints Ingrid Müller as chief operating officer By Investing.com - Investing.com South Africa
Evotec SE stock (DE0005664809): Is its drug discovery model strong enough to unlock new upside? - AD HOC NEWS
100% Profit Potential in Sight: Vidac Pharma's Chance to Double vs Bayer and Evotec - news.financial
Evotec Q4 2025 slides: strong finish masks segment headwinds By Investing.com - Investing.com Australia
BofA reiterates Evotec stock Underperform rating on execution concerns - Investing.com
Evotec (NASDAQ: EVO) pivots to asset-light model and boosts 2025 liquidity - Stock Titan
Evotec Q4 2025 slides: strong finish masks segment headwinds - Investing.com
Finanzdaten der Evotec Se Adr-Aktie (EVO)
Umsatz
Nettogewinn
Free Cashflow
ENV
5.13%
6.20%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):